CytomX Therapeutics (CTMX) Revenue (2014 - 2026)

CytomX Therapeutics has reported Revenue for 13 years, with the latest figure at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 79.85% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $35.5 million (down 75.91% YoY), and the FY2025 full-year result was $76.2 million, down 44.82% from the prior year.
• Revenue for Q1 2026 stood at $10.3 million, up from $663000.0 in the prior quarter.
• The five-year high for Revenue was $50.9 million in Q1 2025, with the low at $663000.0 in Q4 2025.
• Historically, Revenue has averaged $22.3 million across 5 years, with a median of $23.5 million in 2023.
• Annual changes were most pronounced in 2023 — Revenue jumped 159.94% — and 2025, when it slumped 98.26%.
• CytomX Therapeutics' Revenue stood at $20.1 million in 2022, then jumped by 32.22% to $26.6 million in 2023, then surged by 43.17% to $38.1 million in 2024, then tumbled by 98.26% to $663000.0 in 2025, then surged by 1447.21% to $10.3 million in 2026.
• The last three Revenue figures came in at $10.3 million (Q1 2026), $663000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.